
Ocular Therapeutix (OCUL) Stock Forecast & Price Target
Ocular Therapeutix (OCUL) Analyst Ratings
Bulls say
Ocular Therapeutix is favored because AXPAXLI has already produced positive Phase 3 wet AMD data, with SOL-1 showing superiority to a single aflibercept injection and the program advancing toward an NDA submission expected in 4Q26 under the 505(b)(2) pathway. The thesis is strengthened by SOL-R design features that should improve the odds of success, including screening out patients with early persistent retinal fluid or variability, while interim safety data in the current quarter and more than 300 patients with at least one year of follow-up support the filing. Financially, the company reported $12.9M in revenue, a $94.8M net loss in 3Q26, and $530.6M in cash at the end of September 2026, with management expecting runway into 2028 to fund clinical, pre-commercial, and launch preparations.
Bears say
Ocular Therapeutix is highly dependent on Axpaxli, a Phase 3 candidate for wet AMD and NPDR, so any clinical setback, unexpected safety issue, or unfavorable FDA review of the NDA package could materially impair its main growth driver. Even with positive Phase 3 SOL-1 data, commercialization still faces meaningful hurdles from restrictive labeling risk, competition from entrenched anti-VEGF products, reimbursement pressure, and the need for physician and payer adoption. Financially, the company has one revenue-generating product, has incurred significant losses since inception, and will likely need substantial additional capital to fund development, commercialization, and further indications, leaving the stock exposed to dilution and high volatility.
This aggregate rating is based on analysts' research of Ocular Therapeutix and is not a guaranteed prediction by Public.com or investment advice.
Ocular Therapeutix (OCUL) Analyst Forecast & Price Prediction
Start investing in Ocular Therapeutix (OCUL)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Ocular Therapeutix (OCUL) Forecast
Ocular Therapeutix (OCUL) Analyst Forecast & Price Prediction
Start investing in Ocular Therapeutix (OCUL)
Order type
Buy in
Order amount
Est. shares
0 shares